Regeneron Pharmaceuticals Inc (REGN)

577.13
+2.52(+0.44%)
After Hours
577.13
0.00(0.00%)
- Real-time Data
  • Volume:
    362,192
  • Bid/Ask:
    570.30/585.15
  • Day's Range:
    570.38 - 580.87

REGN Overview

Prev. Close
577.13
Day's Range
570.38-580.87
Revenue
9.2B
Open
577.12
52 wk Range
441.3-657.24
EPS
35.35
Volume
362,192
Market Cap
59.77B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
737,567
P/E Ratio
16.33
Beta
0.13
1-Year Change
-8.69%
Shares Outstanding
103,556,326
Next Earnings Date
Aug 05, 2021
What is your sentiment on Regeneron Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Regeneron Pharmaceuticals Inc News

Regeneron Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellBuyStrong Buy
Technical IndicatorsStrong BuySellSellSellStrong Buy
SummaryStrong BuyNeutralSellNeutralStrong Buy

Regeneron Pharmaceuticals Inc Company Profile

Regeneron Pharmaceuticals Inc Company Profile

Employees
9123

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Read More
  • Regn sets to reach its peak👍
    0
    • As far as i can see, insiders are exercising cheap options to sell immediately for good profit; but there’s no one of the board buying at the market, to give some confidence on the company; to myself it’s a pity of time and wasted capital stuck on this
      0
      • possibly acquiring Inovio?
        0
        • They shouldn’t; then the 500$ line will be lost forever
          1
      • 490.08
        1
        • 483.75
          0
          • hello
            0
            • 100
              0
              • hello
                0
                • I smell billions
                  0
                  • hi
                    0
                    • 700
                      0
                      • 500
                        0
                        • topped just above 500 and down back to 480, what's next?
                          0
                          • earnings tomorrow ;)
                            0
                        • I bought @470 I'll comeback to discuss more at @600 :)))
                          0
                          • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
                            0
                            • digipharm going to be big check it out
                              0
                              • Quick buy call on SNDX pharma with 20% upside cap today..17.5 call option target 5$
                                0
                                • EPS forecast is going to 'double' to 16 !! (august earnings) . go go go
                                  0
                                  • Going up !! Target 640!
                                    0
                                    • Whwre you see that
                                      1
                                    • earnings, analists, news, ... read read read
                                      0
                                  • Clinical phae 3 data was just released, showing that 50% dose of REG-COV is also effective, even 12.5% works... This should significantly increase the revenue they can tap from the antibody cure, now that the numbers are surging all over Europe
                                    0
                                    • Do they pay dividends?
                                      1
                                      • nopp
                                        0
                                    • Heading south, ey?
                                      0
                                      • did we hit bottom yet?
                                        2
                                        • why is it going down for weeks ?
                                          0
                                          • ARKG is buying REGN now to hedge against a correction and sell them to buy more growth stock when that happens. However the valuation is indeed quite attractive.
                                            0
                                        • why is it going down fir weeks ?
                                          0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.